The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
The effort has implications for international travel and allocating vaccines – but the precise quantitative tests necessary for this do not, as yet, exist.
Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
A shock US rejection delays approval by at least two years and makes Abbvie, which had given up rights five years ago, look smart.
The Juno/Wuxi venture will soon become one of just a few Chinese cell therapy players with a stock exchange listing.
A new competitor enters the exon 53 skipping niche, and might well take it over.
Launching a suite of Covid-19 diagnostics could not prevent Roche’s first-half profits sliding 5%.
The company’s chief financial officer leaves on the eve of its second-quarter earnings report; should investors be worried?